BG63073B1 - Фармацевтични състави и лекарствени средства за профилактика и лечение на ендотелиални нарушения - Google Patents

Фармацевтични състави и лекарствени средства за профилактика и лечение на ендотелиални нарушения Download PDF

Info

Publication number
BG63073B1
BG63073B1 BG100930A BG10093096A BG63073B1 BG 63073 B1 BG63073 B1 BG 63073B1 BG 100930 A BG100930 A BG 100930A BG 10093096 A BG10093096 A BG 10093096A BG 63073 B1 BG63073 B1 BG 63073B1
Authority
BG
Bulgaria
Prior art keywords
endothelial
treatment
dab
compounds
disorders
Prior art date
Application number
BG100930A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG100930A (en
Inventor
Eike Noack
Georg Kojda
Original Assignee
Isis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharma Gmbh filed Critical Isis Pharma Gmbh
Publication of BG100930A publication Critical patent/BG100930A/xx
Publication of BG63073B1 publication Critical patent/BG63073B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG100930A 1994-03-30 1996-10-22 Фармацевтични състави и лекарствени средства за профилактика и лечение на ендотелиални нарушения BG63073B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4410997A DE4410997A1 (de) 1994-03-30 1994-03-30 Pharmazeutische Zubereitungen und Arzneistoffe zur Prävention und Behandlung endothelialer Dysfunktionen
PCT/DE1995/000421 WO1995026725A1 (de) 1994-03-30 1995-03-28 Pharmazeutische zubereitingen und arzneistoffe zur prävention und behandlung endothelialer dysfunktion

Publications (2)

Publication Number Publication Date
BG100930A BG100930A (en) 1997-07-31
BG63073B1 true BG63073B1 (bg) 2001-03-30

Family

ID=6514213

Family Applications (1)

Application Number Title Priority Date Filing Date
BG100930A BG63073B1 (bg) 1994-03-30 1996-10-22 Фармацевтични състави и лекарствени средства за профилактика и лечение на ендотелиални нарушения

Country Status (19)

Country Link
EP (1) EP0752858A1 (fi)
JP (1) JPH09510979A (fi)
CN (1) CN1150387A (fi)
BG (1) BG63073B1 (fi)
CA (1) CA2186783A1 (fi)
CZ (1) CZ283696A3 (fi)
DE (2) DE4410997A1 (fi)
EE (1) EE9600139A (fi)
FI (1) FI963883A (fi)
HU (1) HU220165B (fi)
IS (1) IS4365A (fi)
LT (1) LT4310B (fi)
LV (1) LV11666B (fi)
MX (1) MX9604434A (fi)
NO (1) NO964102D0 (fi)
PL (1) PL316528A1 (fi)
SI (1) SI9520047A (fi)
SK (1) SK121896A3 (fi)
WO (1) WO1995026725A1 (fi)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9423868D0 (en) * 1994-11-25 1995-01-11 Wellcome Found Compounds for use in medicine
DE19654895C2 (de) * 1996-02-07 2000-07-27 Sanol Arznei Schwarz Gmbh Detektionsverfahren
DE19604361C2 (de) * 1996-02-07 1999-01-14 Sanol Arznei Schwarz Gmbh Verwendung gasdichter Primärpackmittel für pharmazeutische Zusammensetzungen
DE19726812A1 (de) * 1997-06-25 1999-01-07 Isis Pharma Gmbh Neue Derivate des Pentaerythrits, deren Herstellung und Verwendung sowie Intermediate zur Synthese derselben
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
USRE37234E1 (en) 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
ZA989356B (en) * 1997-10-16 1998-11-16 Isis Pharma Gmbh Pharmaceutical preparations
DE19745622A1 (de) * 1997-10-16 1999-04-22 Isis Pharma Gmbh Neue Salpetersäureester des Pentaerythrits
DE69830069T3 (de) * 1997-10-17 2012-02-09 Ark Therapeutics Ltd. Verwendung von hemmern des renin-angiotensin systems zur behandlung von hypoxie oder verringertem stoffwechsel
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
EP1087926A2 (de) * 1998-06-24 2001-04-04 Alpharma-Isis GmbH & Co. KG Analytische substrate und antioxidative mittel
US6465463B1 (en) 1999-09-08 2002-10-15 Nitromed, Inc. Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
US7235237B2 (en) 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7708989B2 (en) 1999-10-29 2010-05-04 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7537785B2 (en) 1999-10-29 2009-05-26 Nitromed, Inc. Composition for treating vascular diseases characterized by nitric oxide insufficiency
WO2001035961A1 (en) 1999-10-29 2001-05-25 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
ES2258365B1 (es) * 2003-10-03 2007-12-01 Lacer, S.A. Derivados de disulfuro, sulfuro, sulfoxido y sulfona de azucares ciclicos y sus usos.
WO2008124505A2 (en) * 2007-04-05 2008-10-16 Ironwood Pharmaceuticals,Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
MA34330B1 (fr) * 2010-05-27 2013-06-01 Merck Sharp & Dohme Activateurs de guanylate cyclase soluble
RU2467748C1 (ru) * 2011-08-08 2012-11-27 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" Производное 3-(2,2,2-триметилгидразиний)пропионата - глицинат 3-(2,2,2-триметилгидразиний)пропионат калия, обладающее эндотелиопротекторной активностью
JP5360939B2 (ja) * 2011-09-28 2013-12-04 国立大学法人徳島大学 ニトロソニフェジピン誘導体を有効成分とする動脈硬化症治療剤

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR984523A (fr) * 1949-02-10 1951-07-06 Phosphate de trinitro-triéthanolamine et procédé de préparation
DE1695897C3 (de) * 1966-07-04 1979-02-15 Takeda Chemical Industries Ltd N-Acyl-sydnonimine, deren Salze, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
AU465217B2 (en) * 1971-04-29 1975-09-18 American Home Products Corporation Mononitrte esters of 1,4:3, 6-dianhydro-d-glucitol
US3886186A (en) * 1971-04-29 1975-05-27 American Home Prod Mononitrate esters of 1,4:3,6-dianhydro-d-glucitol
DE2532124C3 (de) * 1975-07-18 1979-04-19 Cassella Ag, 6000 Frankfurt Verfahren zur Herstellung von 4-Amino-morpholin
US4200640A (en) * 1976-04-02 1980-04-29 Chugai Seiyaku Kabushiki Kaisha Nitric ester of N-(2-hydroxyethyl)nicotinamide and pharmaceutical use
DE2623800C3 (de) * 1976-05-28 1978-11-23 Sanol Schwarz-Monheim Gmbh, 4000 Duesseldorf Obersättigte wässerige Isosorbiddinitrat-Lösung, Herstellungsverfahren und Verwendung
US4065488A (en) * 1977-02-24 1977-12-27 American Home Products Corporation Process for preparing 1,4:3,6-dianhydro-D-glucitol 2-nitrate
DE2903927C2 (de) * 1979-02-02 1981-03-12 Sanol Schwarz-Monheim Gmbh, 4019 Monheim Verfahren zur selektiven Herstellung von Isosorbid-5-nitrat
DE3028873C2 (de) * 1980-07-30 1983-10-27 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur Herstellung von 1,4 zu 3,6-Dianhydro-D-glucit-5-nitrat (Isosorbid-5-nitrat)
DE3102947A1 (de) * 1981-01-29 1982-09-02 Heinrich Mack Nachf., 7918 Illertissen Verfahren zur herstellung von isosorbid-5-nitrat
FR2500835A1 (fr) * 1981-02-27 1982-09-03 Poudres & Explosifs Ste Nale Procede de synthese des mononitrates d'isosorbide
DE3117612A1 (de) * 1981-05-05 1982-11-25 Cassella Ag, 6000 Frankfurt Verfahren zur herstellung von isosorbid-5-nitrat
DE3124410A1 (de) * 1981-06-22 1983-01-05 Heinrich Mack Nachf., 7918 Illertissen Verfahren zur herstellung von isosorbid-2-nitrat
JPS5910513A (ja) * 1982-07-12 1984-01-20 Nitto Electric Ind Co Ltd 医薬製剤
DE3325652A1 (de) * 1983-07-15 1985-01-24 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Feste, stabile isosorbid-5-mononitrat enthaltende arzneimittelzubereitungen und verfahren zu ihrer herstellung
DE3328094A1 (de) * 1983-08-04 1985-02-21 H. Trommsdorff GmbH & Co, 5110 Alsdorf Phlegmatisierte pharmazeutische zubereitung von explosionsfaehigen salpetersaeureestern
DE3479800D1 (en) * 1983-11-25 1989-10-26 Toshin Chemical Co A method for the preparation of isosorbide-5-nitrate and sodium isosorbide-5-nitrate hydrate as a precursor thereof
DD244980A1 (de) * 1985-12-18 1987-04-22 Isis Chemie Zwickau Veb Verfahren zur herstellung von n-morpholinoaminoacetonitril und dessen hydrochlorid
DD293492A5 (de) * 1987-11-26 1991-09-05 Isis-Chemie Gmbh,De Verfahren zur herstellung einer glyceroltrinitrat-arzneiform mit gleichmaessig verzoegerter arzneistofffreisetzung
US5284872A (en) * 1989-09-12 1994-02-08 Schwarz Pharma Ag Nitrato alkanoic acid derivatives, methods for their production, pharmaceutical compositions containing the derivatives and medicinal uses thereof
DE4007705C1 (fi) * 1990-03-10 1991-09-26 G. Pohl-Boskamp Gmbh & Co. Chemisch-Pharmazeutische Fabrik, 2214 Hohenlockstedt, De
DE4038203A1 (de) * 1990-11-30 1992-06-04 Kali Chemie Pharma Gmbh Pharmazeutische spray-zubereitungen mit coronaraktiven wirkstoffen
US5385937A (en) * 1991-04-10 1995-01-31 Brigham & Women's Hospital Nitrosation of homocysteine as a method for treating homocysteinemia

Also Published As

Publication number Publication date
IS4365A (is) 1996-09-25
AU2134595A (en) 1995-10-23
LT96148A (en) 1997-12-29
NO964102L (no) 1996-09-27
EE9600139A (et) 1997-04-15
CA2186783A1 (en) 1995-10-12
DE4410997A1 (de) 1995-10-26
MX9604434A (es) 1997-12-31
SK121896A3 (en) 1998-10-07
CZ283696A3 (cs) 1998-03-18
EP0752858A1 (de) 1997-01-15
PL316528A1 (en) 1997-01-20
HU220165B (hu) 2001-11-28
LV11666A (lv) 1997-02-20
NO964102D0 (no) 1996-09-27
HU9602671D0 (en) 1996-11-28
JPH09510979A (ja) 1997-11-04
FI963883A0 (fi) 1996-09-27
LV11666B (en) 1997-06-20
DE19580261D2 (de) 1997-05-28
LT4310B (lt) 1998-03-25
BG100930A (en) 1997-07-31
CN1150387A (zh) 1997-05-21
FI963883A (fi) 1996-09-27
HUT76676A (en) 1997-10-28
WO1995026725A1 (de) 1995-10-12
SI9520047A (en) 1997-06-30
AU698359B2 (en) 1998-10-29

Similar Documents

Publication Publication Date Title
BG63073B1 (bg) Фармацевтични състави и лекарствени средства за профилактика и лечение на ендотелиални нарушения
US5973011A (en) Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction
US5393772A (en) Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
EP0861666B1 (en) Pharmaceutical composition for use in treatment of diabetes
US20080300253A1 (en) Treatment of inflammatory disorders with praziquantel
KR100540618B1 (ko) 의약 조성물
CZ20012343A3 (cs) Kombinace inhibitorů transportu ľlučové kyseliny v ileu a derivátů kyseliny nikotinové pro kardiovaskulární indikace
WO1999013875A1 (en) Use of nitroxides for the treatment of essential hypertension
JP2002537258A5 (fi)
WO2007149285A2 (en) Method of improved diuresis in individuals with impaired renal function
MXPA06011823A (es) Terapia de combinacion, que comprende un antagonista del receptor de la adenosina a1 y un inhibidor de la aldosterona.
EP0425909A2 (en) Method for rehabilitating the vasorelaxant action of the coronary arteries impaired through atherosclerosis or hypercholesterolemia employing an ace inhibitor
US6034110A (en) Method for preventing onset of restenosis after angioplasty employing an RXR-specific retinoid and a PPARγ ligand
Burnier et al. Pharmacokinetic optimisation of angiotensin converting enzyme (ACE) inhibitor therapy
JP2001508795A (ja) Ｍｔｐインヒビター単独またはこれと他のコレステロール降下薬を組合せて用いる心臓血管疾患の発病の危険を予防または軽減する方法
KR100895031B1 (ko) 지질 농후 플라크의 감소, 안정화 및 파열 방지 방법
JPS6056920A (ja) 脂質レベルの低減方法
CA2355645A1 (en) Increasing brain glucose utilization
US6172115B1 (en) Method for preventing onset of restenosis after angioplasty employing an RXR-specific retinoid
WO1998043645A1 (fr) Inhibiteurs de la formation de produits de denaturation de proteines glycosylees
JP2008094852A (ja) 医薬
JPH1081632A (ja) 医 薬
JP2000007562A (ja) レトロウイルス感染に伴う免疫不全発症予防薬及び進行抑制薬
JPH08259590A (ja) 高脂血症治療剤
JPS6314722A (ja) 高脂血症治療剤